Tokyo Tape
Sign in
← M3

Quarterly report · Q3

2413.TEDINET S100SS2U
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥179.2bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥63.4bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥175.2bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥62.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥55.0bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥20.4bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥58.7bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥22.4bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥57.3bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥20.0bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥60.2bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.2bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥36.6bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥13.2bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥39.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥38.9bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥13.8bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥41.8bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥15.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥463.8bnat 2023-12-31Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥380.7bnat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥112.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥351.1bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥297.4bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥337.1bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥290.7bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥143.1bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥109.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥35.6bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥33.4bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥26.3bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.6bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥13.9bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.7bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥53.932023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.452023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥57.862022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.422022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥53.892023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.442023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥57.822022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.42022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio72.7%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio76.4%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥2.6bn
Reconciling Itemsreconcilingrevenue2023-10-01 → 2023-12-31−¥779m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥2.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-10-01 → 2023-12-31−¥779m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥459m
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2023-12-31−¥584m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥12.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥3.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥12.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥3.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥31m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥10m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥3.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥549m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥20.3bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥6.5bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥248m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥32m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥5.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥1.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-12-31¥71.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2023-10-01 → 2023-12-31¥26.0bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-12-31¥69.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2023-10-01 → 2023-12-31¥25.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥2.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥710m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-12-31¥30.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2023-10-01 → 2023-12-31¥11.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-12-31¥52.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2023-10-01 → 2023-12-31¥19.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-12-31¥52.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2023-10-01 → 2023-12-31¥19.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥15m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥4m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-12-31¥12.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2023-10-01 → 2023-12-31¥5.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥23.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥23.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥10m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥3m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥2.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥842m
—segment totalrevenue2023-04-01 → 2023-12-31¥179.8bn
—segment totalrevenue2023-10-01 → 2023-12-31¥63.4bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥177.3bn
—segment totalrevenue external2023-10-01 → 2023-12-31¥62.7bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥2.5bn
—segment totalrevenue intersegment2023-10-01 → 2023-12-31¥759m
—segment totalsegment profit2023-04-01 → 2023-12-31¥54.9bn
—segment totalsegment profit2023-10-01 → 2023-12-31¥20.5bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥418m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥11.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥3.1bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥10.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥2.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥623m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥178m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥4.2bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥734m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥6.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥521m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥174m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.0bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-12-31¥69.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-10-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-12-31¥67.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-10-01 → 2022-12-31¥26.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥739m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-12-31¥32.1bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-10-01 → 2022-12-31¥13.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-12-31¥47.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-12-31¥47.2bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥21m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-12-31¥13.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-10-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥27.5bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥304m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥3.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥917m
—segment totalrevenue2022-04-01 → 2022-12-31¥176.6bn
—segment totalrevenue2022-10-01 → 2022-12-31¥62.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥172.8bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥61.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥3.8bn
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥1.1bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥59.5bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥22.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 773
ItemContextValueUnit
Payments for acquisition of businesses inv cf IFRSCurrentYTDDuration-4110000000JPY
Other inv cf IFRSPrior1YTDDuration5000000JPY
Other inv cf IFRSCurrentYTDDuration117000000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-8601000000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-26313000000JPY
Dividends paid to owners of parent fin cf IFRSPrior1YTDDuration-10860000000JPY
Dividends paid to owners of parent fin cf IFRSCurrentYTDDuration-12895000000JPY
Capital contribution from non controlling interests fin cf IFRSPrior1YTDDuration140000000JPY
Capital contribution from non controlling interests fin cf IFRSCurrentYTDDuration13109000000JPY
Dividends paid to non controlling interests fin cf IFRSPrior1YTDDuration-1790000000JPY
Dividends paid to non controlling interests fin cf IFRSCurrentYTDDuration-2464000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSPrior1YTDDuration-5236000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSCurrentYTDDuration-0JPY
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration－JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration19930000000JPY
Repayments of borrowings fin cf IFRSPrior1YTDDuration-240000000JPY
Repayments of borrowings fin cf IFRSCurrentYTDDuration-1042000000JPY
Proceeds from issuance of shares fin cf IFRSPrior1YTDDuration72000000JPY
Proceeds from issuance of shares fin cf IFRSCurrentYTDDuration73000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-2852000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-2853000000JPY
Other fin cf IFRSPrior1YTDDuration24000000JPY
Other fin cf IFRSCurrentYTDDuration4000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-20741000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration13862000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration1460000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration1641000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration5504000000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration24805000000JPY
Cash and cash equivalents IFRSPrior2YearInstant104253000000JPY
Cash and cash equivalents IFRSPrior1YearInstant118319000000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant109757000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant143123000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember67410000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember20081000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember10837000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember27226000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember47240000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember172793000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember2362000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration175155000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember2354000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember521000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember623000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember304000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember21000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember3823000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember73000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-3895000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass